Here is a selection of recent PharmaVentures press releases...
PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva's Hlovovec Production Facility to Wood Pharma Holding
OXFORD, England, December 19, 2012 /PRNewswire/ -- PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi's divestment of its Zentiva subsidiary's production plant in Hlohovec, Slovakia. Under the terms of this agreement, Sanofi will sell to Wood Pharma Holding the production, packaging and distribution part of its Zentiva business covering Active Pharmaceutical Ingredients (APIs) and Drug Products activities. The sale includes transfer of the production facilities and employees. Future co-operation in the purchase of drug products and APIs produced by Wood Pharma Holding in Hlohovec in the next five years has also been agreed.
Stephen Waterman joins PharmaVentures
Oxford, UK, 18 October 2012 - PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing PharmaVentures’ corporate finance capabilities and offerings to the global healthcare and investment communities.
PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund
Oxford, UK, March 21, 2012: Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index’s largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).
Protecting Cash Flow Through Licensing Terms is Critical for Biotech Success
Oxford, UK, March 19, 2012: The pharmaceutical and biotechnology industry is undergoing considerable change as the patent cliff looms, fostering invention and change, and a strong need for successful partnering. There are also new opportunities to develop in emerging and emerged new markets. What impact are these changes having on companies as they seek partners, to strike the best deal? How can companies be sure that the deal terms they achieve, and associated royalties, are the best possible? The terms of licensing deals are turning back in favour of cash-rich pharmaceutical companies, and there are key lessons to be learned by any aspiring dealmaker.